drugset

drugset / Trial / NCT00002332

A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs

NCT00002332 ↗

Phase 2 Completed 60 enrolled Immunobiology Research Institute

Double-blindTreatment

Summary

To evaluate the mechanism whereby thymopentin appears to retard the progressive immune suppression attributable to HIV infection.

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Thymopentin	Peptide	—	Subcutaneous

Indications